EMD Serono Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash
Cohort analyses from the WILLOW study reveal clear proof of concept in patients with CLE and SLE with active lupus rash, showing clinically meaningful improvement in disease activity at Week 16
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
Lupus rash can lead to physical discomfort and emotional distress, highlighting the need for effective treatments to manage its signs and symptoms
Article content
Article content
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor, demonstrating clinically meaningful reduction in disease activity in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) with active lupus rash. The findings are from Cohort A of the Phase 2 WILLOW study ( NCT05162586). Results will be presented at the 16 th International Congress on Systemic Lupus Erythematosus (LUPUS 2025), taking place May 21-24 in Toronto.
Article content
WILLOW is a global, multicenter, randomized, placebo-controlled Phase 2 study evaluating three doses of enpatoran taken twice daily (25 mg, 50 mg and 100 mg) versus placebo plus standard of care (SoC) over 24 weeks. The study features a unique design across two lupus cohorts, including both patients with active SLE and CLE. Cohort A focused on patients with CLE or SLE with active lupus rash and evaluated organ-specific disease activity using the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score, a well-defined endpoint in CLE studies that measures different aspects of mucocutaneous manifestations. Cohort B was designed to evaluate the effect of enpatoran on systemic disease activity of SLE patients with the BICLA response endpoint.
Article content
Cohort A met its primary endpoint, demonstrating a dose-response relationship and showing a clinically meaningful improvement in CLASI-A scores at Week 16 (p = 0.0002). Additionally, at Week 24 up to 91.3% of patients receiving enpatoran achieved a CLASI-50 response (≥50% improvement from baseline), and up to 60.9% achieved a CLASI-70 response (≥70% improvement), compared with 38.5% and 11.5%, respectively, in the placebo group. In this cohort, enpatoran was well-tolerated, and exhibited a manageable safety profile consistent with previous studies, with no new safety signals identified.
Article content
'Lupus can make navigating everyday life difficult. The skin manifestation, known as lupus rash, often comes with persistent itching, which can lead to scarring and hair loss. This can significantly impact the physical, emotional and social well-being of those living with lupus, underscoring the urgent need for effective treatments,' said Jan Klatt, Head of Development Unit Neurology & Immunology for the Healthcare business of Merck KGaA, Darmstadt, Germany. 'We are encouraged by the WILLOW results, where we observed clinically meaningful efficacy with a favorable safety profile in people living with lupus rash. Based on these results, discussions with health authorities on a global Phase 3 program with enpatoran are underway.'
Article content
In addition, and confirming the biological activity, treatment with enpatoran in Cohort A also led to a rapid reduction in interferon gene signature scores beginning at Week 2, which was maintained to Week 24, confirming the involvement of the TLR7/8 pathway in interferon activation in CLE. Overall, evidence from the WILLOW study supports the continued development of enpatoran as a treatment for autoimmune diseases like lupus.
Article content
On Cohort B of the WILLOW study, promising efficacy results were observed in prespecified subpopulations, even though the primary endpoint of dose response was not met. The full readout from this cohort will be presented at the European Alliance of Associations for Rheumatology Congress (EULAR 2025).
Article content
Principal investigator Prof. Eric Morand of Monash University and Monash Health, said, 'These new findings offer promising evidence that, with enpatoran, we may be able to advance outcomes, which remain suboptimal for most patients. The data from the WILLOW study further our understanding of TLR7/8 inhibition in SLE and CLE, which is a novel mechanism of action that may offer new hope for patients.'
Article content
Toll-like receptors (TLR)7 and TLR8 play a relevant role in lupus pathogenesis and are associated with severe manifestations of the disease. By inhibiting these key disease drivers, enpatoran's unique proposed mechanism of action aims to enhance therapeutic efficacy while preserving the body's immune response, potentially overcoming limitations of existing lupus therapies.
Article content
About Enpatoran
Article content
Enpatoran is a selective Toll-like receptor (TLR)7/8 inhibitor under investigation for the treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). By inhibiting TLR7/8 activation, enpatoran may help reduce pro-inflammatory cytokines and autoantibody production, potentially addressing underlying mechanisms of chronic inflammation and disease progression in lupus. With its novel proposed mechanism of action and oral administration, enpatoran has the potential to be a first-in-class treatment for patients across lupus conditions. Enpatoran is currently under clinical investigation and is not approved for any use anywhere in the world.
Article content
WILLOW ( NCT05162586) is a randomized, double-blind, placebo-controlled Phase 2 proof of concept and dose-finding study designed to evaluate the efficacy and safety of enpatoran in patients with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). The study incorporates a basket design, including two cohorts – Cohort A including patients with CLE or SLE with active lupus rash and Cohort B including patients with active SLE. The WILLOW study aims to advance the understanding of enpatoran's therapeutic potential and to help address significant unmet needs in lupus treatment.
Article content
About Lupus Erythematosus
Article content
Lupus erythematosus is a chronic autoimmune disease that can affect various parts of the body, including the skin, joints, kidneys and other organs. It occurs when the immune system mistakenly attacks healthy tissues, leading to inflammation, pain and potential organ damage. There are multiple types of lupus, with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) being two primary forms. Symptoms can range from mild to life-threatening, often including fatigue, joint pain, rashes and organ involvement. Lupus disproportionately impacts women and people of color, and despite available treatments, many patients experience unmet needs due to limited efficacy or side effects.
Article content
EMD Serono in Neurology and Immunology
Article content
EMD Serono has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company's current MS portfolio includes two products for the treatment of relapsing MS – Rebif ® (interferon beta-1a) and MAVENCLAD ® (cladribine) tablets. EMD Serono aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to EMD Serono's commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and generalized myasthenia gravis (gMG).
Article content
About EMD Serono, Inc.
Article content
EMD Serono – the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada – aspires to create, improve and prolong life for people living with difficult-to-treat conditions like infertility, multiple sclerosis and cancer. The business is imagining the future of healthcare by working to translate the discovery of molecules into potentially meaningful outcomes for people with serious unmet medical needs. EMD Serono's global roots go back more than 350 years with Merck KGaA, Darmstadt, Germany. Today, the business has approximately 1,050 employees around the country with commercial, clinical and research operations in Massachusetts. www.emdserono.com.
Article content
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries.
Article content
The company holds the global rights to the name and trademark 'Merck' internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Article content
Article content
Article content
Article content
Article content
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
43 minutes ago
- Globe and Mail
Globe Climate: The rise of weather content on social media
If you're reading this on the web or someone forwarded this e-mail newsletter to you, you can sign up for Globe Climate and all Globe newsletters here. Good afternoon, and welcome to Globe Climate, a newsletter about climate change, environment and resources in Canada. A manatee was recently spotted off the coast of Massachusetts for the first time in almost a decade. The threatened species usually makes its habitat in warmer southern Gulf waters, so scientists want to monitor its condition to see if a rescue is necessary. In 2008 and 2009, different manatees were sighted in Cape Cod Bay – the furthest north the animals have ever been identified. Both were eventually rescued. Anyone who sees the manatee is asked to document their GPS position and call the stranding network hotline, (508) 743-9548. Now, let's catch you up on other news. For this week's deeper dive, we closer look at the online world of watching weather. How often do you check your weather app? Or... weather apps? Online culture reporter Samantha Edwards recently took a deep dive into the new big world of weather data. Once the domain of professionals, climate information gathered from satellites and radar models are now easily accessible online, giving amateur forecasters an unprecedented amount of raw data. 'I immersed myself into the digital world of weather nerds, amateur forecasters and content creators. I joined niche online forums, subreddits and Facebook groups, subscribed to YouTubers who livestream during extreme weather events, and followed weather influencers,' she wrote in the morning update newsletter. With a plethora of new weather apps, we have access to real-time information that can help us better plan our lives and time outdoors – from where there will be heavy rain to extreme heat. On Reddit and niche online forums, weather nerds analyze and debate the output of forecasts. On YouTube and TikTok, 'storm streamers' go live for hours during extreme weather events, providing real-time updates and sharing on-the-ground photos sent in from their devoted followers. But the flood of data can also consume us, lead to misinformation and heighten climate anxiety while at the same time diluting important updates about flooding and wildfire threats. For the past few summers, Aspen Murray has started to check a new data point every day on her weather app: air quality. 'Getting accustomed to checking the air quality has been something that's really made me think more about my climate anxiety,' she said. 'Growing up, that's something that I never would have thought of or worried about.' Experts also warn that the overexposure to weather warnings, especially if they're poorly worded or not local, can lead to 'alert fatigue' and may result in tuning out crucial information. Plus, during extreme weather events, disinformation from high-profile conspiracy theorists is drowning out emergency response efforts. On Facebook, Samantha stumbled upon a group called Ontario Storm Reports, which was started by the former storm chaser Adam Skinner and now has tens of thousands of members. He says that the majority of people who post in the group, and also watch his livestreams during severe weather, have weather anxiety but find the knowledge more comforting. 'The unknown is much more scary,' he said. Sarah Goodman: Ottawa must prioritize climate tech in Canada's new defence strategy Stephen Maher: The people opposing Nova Scotia's ban on accessing the woods don't understand our culture Julia Zarankin: To my surprise, I learned that birding can be an adrenaline-fuelled extreme sport Conservatives plan national campaign to scrap zero-emission vehicle mandate Conservative Leader Pierre Poilievre pledged that his party will embark on a national campaign to push the Liberal government to scrap the policy he's dubbed the 'Carney tax.' Poilievre led the charge as the Conservatives attacked the consumer carbon price over the last two years, which eventually played a role to end the so-called carbon tax earlier this year. Now the Conservative leader claims the Liberal EV mandates 'would literally erase many small towns from the map.' We've launched the The Climate Exchange, an interactive, digital hub where The Globe answers your most pressing questions about climate change. We have been collecting hundreds of questions and posing them to experts. The answers can be found with the help of a search tool developed by The Globe that makes use of artificial intelligence to match readers' questions with the closest answer drafted. You can ask a question using this form. We want to hear from you. E-mail us: GlobeClimate@ Do you know someone who needs this newsletter? Send them to our Newsletters page.
National Post
an hour ago
- National Post
The remarkable ex-Leaf Mark Kirton succumbs to ALS
Everyone should have a Mark Kirton in their lives Article content Someone who makes today better than yesterday. Someone who makes tomorrow better than today. Article content Article content There aren't many of them in our world — those built-in genuine optimists who you visit and walk away feeling better about the world, about your life, about the sun that is shining because you spent some time with him. Sometimes it may have been just a visit, or a phone call or a text message or just an email. Article content Article content But always with a smile, maybe a joke, maybe a little laughter, something to feel right about when really there wasn't all that much to smile or laugh about. The former hockey player, Mark Kirton lost his battle with the dreadful disease ALS, also known as Lou Gehrig's Disease, on the weekend and I don't know if I've ever known anyone quite like him before, or anyone I admired more. Article content We first met in 2021 when he went public with his personal fight and from there a relationship was born. ALS is a monster that takes away your life, bite by bite, piece by piece. It's different for everyone suffering. Some lose their hands first. Some lose their feet. Some are confined to wheelchairs. Some can speak, some can't. Some can see, some can't, It's one part, then another, no timetable for how it goes or how it tears your life apart. Article content Kirton was still selling real estate in Oakville when we first met, working from home, working from a wheelchair, still talking fast, smiling, pushing the product, forever ready to make the next deal. Article content But as he was still working, he began to turn his work to his own disease. What he could go for ALS? How he could find a way to raise more money? Why is it there were drugs in America that weren't available in Canada? Why is it there wasn't enough known about the disease and not enough research being done. Article content He had more questions than answers, and no where to turn for money. Article content So he started ALS Action Canada and began fundraisers for the disease. He wasn't a big name — he wasn't his former teammate, Borje Salming — but he was so engaging. Article content He got the Canadian NHL teams involved in fundraising. He started the ALS Super Fund, which all NHL clubs began events to contribute to. From ALS Action Canada to the ALS Super Fund, he started PALS — an organization for people suffering from ALS. Article content He wanted to connect people going through the same difficulties. He wanted more communication. Just last week, he had planned to meet with television's Ron Maclean and former Maple Leaf captain, Darryl Sittler, to get to work on his latest project.
CTV News
an hour ago
- CTV News
Prince County Hospital in P.E.I. reinstates Intensive Care Unit
The Prince County Hospital (PCH) in Summerside, P.E.I., reinstated its Intensive Care Unit (ICU) on Aug. 12. This will ensure full critical care capacity is available in western P.E.I., a news release reads. The province now has two operational ICUs at PCH and Queen Elizabeth Hospital. PCH's ICU was temporarily downgraded in May 2023 due to staff shortages, especially in specialized critical care roles. The hospital was able to provide critical care but patients requiring higher acuity care were transferred to Charlottetown. 'This is a moment of deep appreciation for our critical care teams,' said Melanie Fraser, CEO of Health PEI. 'We are incredibly grateful to the health care professionals at both PCH and QEH for their dedication over the past few years. Their collaboration, resilience, and commitment to patients made it possible to create a fully integrated provincial critical care program.' Health PEI says the decision reflects their confidence that coverage is now safely sustainable for staff and patients. The department has also put measures in place to support long-term stability. These measures include strengthened recruitment, improved coordination between hospitals, and ongoing investment in equipment and training. 'Because of the hard work of a lot of people, August 12th looked like any other day,' said Dr. Tyler McDonell, medical director at PCH. 'And that was always the goal—safe, seamless care delivered here at PCH, supported by a system that works together. We know there's more work ahead, but there was a real sense of accomplishment. We did this together.' Health PEI also announced oncology services had returned to PCH last week. 'The last month has required flexibility and patience on the part of patients, loved ones, and staff,' said Dr. Johan Viljoen, Health PEI's chief medical officer. 'I'm happy to report no one's treatment schedule was interrupted during this period, when we moved treatment temporarily due to a staffing shortage. We look forward to this fall when a third oncologist joins the Health PEI team, improving our ability to serve Islanders.' For more P.E.I. news, visit our dedicated provincial page.
